Soleno Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In Redwood Citycaliforniafounded In 1999The Company Focuses On Developing And Commercializing Innovative Therapeutics For Rare Genetic Diseasesit Operates Under The Nasdaq Ticker Slno And Is Led By Ceo Anish Bhatnagaremploying A Team Of 92 Professionals Dedicated To Addressing Unmet Medical Needs In Rare Disease Communities The Company S Lead Product Is Diazoxide Choline Extended Releasedccrtabletscurrently In Phase Iii Trials For Prader Willi Syndromepws Dccr Has Received Breakthrough Therapy Designation From The Fda And Is Set For A Target Action Date In March 2025Soleno Is Also Building A Commercial Team To Support Dccr S Anticipated U Slaunchadditionallythe Company Has Secured Significant Funding To Bolster Its Commercialization Efforts And Actively Engages With Investors And Healthcare Professionals At Industry Conferences
